Clinical trial Recruiting at 1 site Phase1; Phase2 Interventional Ages 18 and up

iEV injections for chronic tennis elbow (lateral epicondylitis)

Official title: A Clinical Trial Study Evaluating the Safety and Preliminary Efficacy of Human Induced Pluripotent Stem Cell-derived Extracellular Vesicles (iEVs) Injection for the Treatment of Lateral Epicondylitis of the Humerus

Run by Shanghai 6th People's Hospital · NCT07111325 · Data updated 2026-11-12

This trial will see if injections of extracellular vesicles made from human induced pluripotent stem cells (iEVs) can help people with chronic tennis elbow reduce pain and improve elbow function.

More Lateral Epicondylitis trials

Quick facts

PhasePhase1; Phase2
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment24 (estimated)
SponsorShanghai 6th People's Hospital
Academic / other
Locations1 site (Shanghai, Shanghai Municipality)
StatusRecruiting
StartedJuly 1, 2023
Main results expectedDecember 1, 2025
Study endsDecember 31, 2025
Registry record updatedAugust 8, 2025
Trial IDNCT07111325 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults with unilateral lateral epicondylitis lasting at least 12 weeks, confirmed by MRI or ultrasound, with pain VAS >3 who have not responded to physical therapy or NSAIDs and who can provide informed consent are ideal candidates.

Probably not a fit

Patients with ipsilateral neurogenic, inflammatory, or systemic joint disease, obvious tendon tear, recent lateral epicondylitis surgery (within 6 months), or other non-tendinopathic causes of elbow pain are unlikely to benefit from this intervention.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-center, phase 1/2 randomized controlled study will test the safety and preliminary efficacy of human iPSC-derived extracellular vesicle (iEV) injections for lateral epicondylitis. Participants will be block-randomized without stratification to one of three arms: iEV injection (experimental), platelet-rich plasma (positive control), or immobilization (negative control). The study plans small cohorts (approximately 6–12 in the experimental arm and 3–6 in each control arm) and will follow patients for changes in pain, grip strength, elbow function, and markers of tendon inflammatory status using clinical exams and imaging. Safety endpoints and adverse events will be closely monitored given the early-phase nature of the intervention.

Why it matters

Potential benefit: If successful, the iEV injections could reduce pain, improve grip strength and elbow function, and help resolve tendon inflammation more quickly than conservative care.

How similar studies have gone: PRP has produced mixed results in prior tennis elbow studies, and iEV injections are a novel biologic approach with very limited published human data to date.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Diagnosed with lateral epicondylitis by clinical symptom examination and MRI or ultrasound, without obvious tendon tear;
* Unilateral lateral elbow pain lasting for more than 12 weeks;
* Pain is provoked by at least 2 of the following methods, with a pain VAS score exceeding 3: maximum grip strength, palpation of the lateral epicondyle of the elbow and surrounding area, resisted dorsiflexion of the wrist or middle finger, or stretching of the forearm extensor muscles under a pain-free grip state;
* Having received physical therapy or non-steroidal anti-inflammatory drug treatment with poor efficacy;
* Individuals with independent behavioral capacity, who have signed the informed consent form themselves.

Exclusion Criteria:

* Complaints of ipsilateral muscle pain caused by other reasons in the past 6 months;
* Presence of ipsilateral neurogenic, inflammatory, or systemic joint diseases;
* A history of previous lateral epicondylitis (LET) surgery in the past 6 months;
* Subjects deemed unsuitable for participating in the trial due to other conditions, as judged by the researcher;
* MRI showing that the injury has involved the lateral collateral ligament, with concurrent cartilage damage.

Where it's running

  • Shanghai Sixth hospital
    Shanghai, Shanghai Municipality, China
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.